SeekingAlpha · Aug 7, 2026
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Inc. (INMB) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsDavid Moss - President, CEO, Treasurer, Secretary &...
IN
NASDAQ · INMB
INmune Bio, Inc.
Healthcare · Biotechnology
$2.32
Up+$0.16 (+7.41%)
Updated Aug 22, 2026, 6:22 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 56.63M
- P/E ratio
- -1.14
- Dividend yield
- 0.00%
- 52-week range
- $1.09 – $2.34
- Volume
- 520.14K
- Avg. volume
- 455.95K
Price performance
INMB price history
1M range · 21 trading sessions · Daily adjusted prices
INMB closed at $2.32 after 21 trading sessions, up 43.21% for the selected period.
- Last close
- $2.32
- Period change
- +43.21%
- Period low
- $1.62
- Period high
- $2.32
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.22 | $2.341 | $2.19 | $2.32 | 520.14K |
| Aug 20, 2026 | $2.20 | $2.24 | $2.145 | $2.16 | 393.67K |
| Aug 19, 2026 | $2.17 | $2.27 | $2.13 | $2.23 | 437.07K |
| Aug 18, 2026 | $2.09 | $2.18 | $2.08 | $2.11 | 231.19K |
| Aug 17, 2026 | $2.17 | $2.195 | $2.105 | $2.13 | 257.53K |
| Aug 14, 2026 | $2.09 | $2.20 | $2.04 | $2.17 | 462.03K |
| Aug 13, 2026 | $2.05 | $2.125 | $2.03 | $2.08 | 208.58K |
| Aug 12, 2026 | $2.08 | $2.106 | $2.01 | $2.04 | 352.1K |
| Aug 11, 2026 | $2.06 | $2.12 | $2.01 | $2.08 | 436.63K |
| Aug 10, 2026 | $2.10 | $2.195 | $2.05 | $2.12 | 462.84K |
| Aug 7, 2026 | $1.97 | $2.105 | $1.92 | $2.085 | 953.03K |
| Aug 6, 2026 | $1.86 | $1.94 | $1.84 | $1.91 | 244.6K |
| Aug 5, 2026 | $1.95 | $1.9599 | $1.79 | $1.90 | 491.22K |
| Aug 4, 2026 | $1.88 | $1.95 | $1.855 | $1.91 | 414.34K |
| Aug 3, 2026 | $1.77 | $1.8697 | $1.72 | $1.85 | 222.9K |
| Jul 31, 2026 | $1.77 | $1.79 | $1.715 | $1.75 | 225.76K |
| Jul 30, 2026 | $1.70 | $1.78 | $1.69 | $1.77 | 134.24K |
| Jul 29, 2026 | $1.72 | $1.82 | $1.68 | $1.69 | 217.45K |
| Jul 28, 2026 | $1.74 | $1.771 | $1.66 | $1.71 | 130.86K |
| Jul 27, 2026 | $1.63 | $1.75 | $1.63 | $1.73 | 180.53K |
| Jul 24, 2026 | $1.69 | $1.71 | $1.61 | $1.62 | 186.1K |
Latest INMB news
The latest Smart Investors Daily articles mentioning INMB.
Stock researchCompany · Overview
INMB research
Overview
Company profile and research snapshot.
Company profile
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 11, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jul 2, 2025 | Maxim Group | Buy | — |
| Jul 1, 2025 | Scotiabank | Sector Underperform | — |
| Jul 1, 2025 | BTIG | Neutral | — |
| Feb 13, 2025 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 6, 2026
INmune Bio (NASDAQ:INMB) Beats Q2 Loss Estimates but Shares Tumble on Business Update
INmune Bio (INMB) Q2 loss beat expectations at -$0.05/share, but stock plunged ~52% on clinical-stage update.
Yahoo · Jul 31, 2026
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million. This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026. After adjusting second-quarter operating cash flows to exclude the approximately
Yahoo · Jul 31, 2026
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial ap
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
